This study explored the binding patterns of the wild type and B.1.618 variant using which revealed that the B.1.618 variant possess a stronger binding affinity for the host ACE2 and escape the neutralizing antibodies.

No abstract

The ultrasonographic evaluation of inferior vena cava (IVC) parameters, particularly the collapsibility index (CI), has been widely used in the assessment of the fluid responsiveness of critically ill patients, but the results are conflicting. In this study, we aimed to investigate the early change in CI after increased intravascular volume (IVV) induced by passive leg raising (PLR). A total of 145 healthy volunteers over 18 years old were enrolled between September and December in 2015. Before and 2 min after PLR, the maximum and minimum IVC diameters (maxIVC and minIVC) were measured by color Doppler ultrasonography, and the difference in CI (ΔCI) was calculated. The heart rate (HR) and noninvasive mean arterial pressure (MAP) were also monitored. We found that there was a significant increase in the mean maxIVC and minIVC values and a reduction in CI. Nevertheless, no significant differences in HR or MAP were observed before or 2 min after PLR. The baseline CI had no relationship with individual characteristics and a multiple linear regression analysis of the ΔCI and individual characteristics showed that age, baseline CI, and BMI were independent variables for ΔCI. In conclusion, IVC-CI measured by ultrasound is useful for the detection of early IVV change induced by 2 min PLR. However, its ability to detect the increased IVV value is influenced by age, BMI, and baseline CI. Moreover, only 50.3% of the subjects had an IVC-CI reduction of more than 10%, making IVC-CI of little value for clinical applications, due to its poor sensitivity.

Ultrasound-measured inferior vena cava (IVC) and abdominal aorta (Ao)-associated parameters have been used to predict volume status for decades, yet research focusing on the impact of individual physical characteristics, including gender, height/weight, body surface area (BSA), and age, assessed simultaneously on those parameters in Chinese children is lacking. The aim of the present study was to explore the impact of individual characteristics on maximum IVC diameter (IVCmax), Ao, and IVCmax/Ao in healthy Chinese children. From September to December 2015, 200 healthy children from 1 to 13 years of age were enrolled. IVCmax and Ao diameters were measured by 2D ultrasound. We found that age (years), height (cm), weight (kg), waist circumference (cm), and BSA (m2) were positively correlated with IVCmax and Ao. Multivariate linear regression showed that age was the only independent variable for IVCmax (mm) in female children, height was the only independent variable for IVCmax in male children, and age was the only independent variable for Ao in both females and males. IVCmax/Ao was not significantly influenced by the subjects’ characteristics. In conclusion, IVCmax and Ao were more susceptible to subjects’ characteristics than IVCmax/Ao. IVCmax/Ao could be a reliable and practical parameter in Chinese children as it was independent of age, height, and weight.

No abstract

No abstract

No abstract

Background Parkinson's disease (PD) is a neurological disorder characterized by motor and gastrointestinal dysfunctions. There is a significant need for more effective treatment options. Resveratrol (RES) is a potent antioxidant and anti-inflammatory phytoalexin known for its health-promoting benefits. However, little is known about its potential in treating PD by modulating the microbial gut-brain axis, and its clinical application has been limited due to poor water solubility, rapid metabolism, and limited systemic bioavailability. Our study aimed to evaluate the therapeutic potential of RHSD, a resveratrol-cyclodextrin inclusion complex, in treating PD through the gut-brain axis in human SNCA-transgenic (A53T) mice PD models.Results We have demonstrated that administering RHSD can prevent neurodegeneration, improve motor skills, and restore the levels of phosphorylated tyrosine hydroxylase in A53T mice, while also leading to a positive impact on gastrointestinal function. Our metagenomic sequencing indicated significant changes in the richness, evenness, and composition of the gut microbiome in A53T mice, with a significant increase in the levels of Lactobacillus murinus, Lactobacillus reuteri, Enterorhabduscaecimuris, Lactobacillus taiwanensis, and Lactobacillus animals following RHSD administration. Furthermore, metabolomics profiling showed that the levels of gut microbiome metabolites were reversed after RHSD treatment, with altered metabolites primarily present in metabolic pathways such as drug metabolism-cytochrome P450, retinol metabolism, purine metabolism, tyrosine metabolism, and methane metabolism. The altered gut microbiota showed significant correlations with microbiota metabolites. With an integrated analysis of microbiota metabolites and host transcriptomics, our research provides insights into the potential interaction between abnormalities in amino acid metabolism, mitochondrial dysfunction, oxidative stress, and neuroinflammation in Parkinson's disease.Conclusions This study illustrates the profound impact of RHSD administration on rectifying gut microbiota dysbiosis and improving the A53T mouse model. We also observed that the proliferation and metabolism of multiple probiotic strains of Lactobacillus were significantly altered. Moreover, our research supports the hypothesis that microbiota-related metabolites could regulate the transcription of host genes, including dopamine receptors and calcium stabilization. Our findings thus highlight the potential of RHSD as a viable therapeutic candidate for treating PD by targeting several signaling pathways of the microbiota-gut-brain axis.